Related Experiment Video
Updated: Jun 19, 2026

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
Published on: November 27, 2019
Phenotype-Specific Dose-Response Patterns of Systemic Inflammation With Hepatic Decompensation in Cirrhosis: A
Shufang Zhang1, Xiaowei Mo2, Caiting Lai1
1School of Nursing, Hainan Medical University, Haikou, China.
Systemic inflammation
Area of Science:
- Hepatology
- Inflammation research
- Clinical biochemistry
Background:
- Systemic inflammation is linked to liver decompensation in cirrhosis.
- The relationship between inflammation and specific decompensation phenotypes requires clarification.
Purpose of the Study:
- To evaluate the association between an inflammation burden index (IBI) and cirrhosis severity.
- To investigate the dose-response patterns of IBI across different decompensation phenotypes (ascites, spontaneous bacterial peritonitis).
Main Methods:
- Developed an IBI integrating IL-6, hs-CRP, neutrophil-to-lymphocyte ratio, and procalcitonin.
- Analyzed IBI association with Child-Turcotte-Pugh (CTP) score, MELD score, ascites, and SBP in 463 cirrhosis patients.
- Utilized restricted cubic splines for dose-response analysis and assessed IBI-sarcopenia interaction.
Main Results:
- High IBI correlated with worse CTP and MELD scores, and increased risk of ascites and SBP.
- Dose-response patterns varied by phenotype: monotonic for CTP, MELD, SBP; inverted-U for ascites, particularly in advanced disease (CTP C).
- Ascites in high-IBI patients showed an immunoparalysis profile; IBI-sarcopenia interaction was supra-additive for ascites.
Conclusions:
- The association between inflammation burden and cirrhosis decompensation is specific to the clinical phenotype.
- The inverted-U pattern for ascites may represent an artifact of advanced disease rather than a biological threshold.
- Findings necessitate prospective validation to confirm the descriptive results.
Related Concept Videos
Cirrhosis II: Pathophysiology
Cirrhosis I: Introduction
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

